TITLE

Risk Factors for Nevirapine-Associated Rash Among HIV-Infected Patients with Low CD4 Cell Counts in Resource-Limited Settings

AUTHOR(S)
Kiertiburanakul, Sasisopin; Sungkanuparph, Somnuek; Charoenyingwattana, Angkana; Mahasirimongkol, Surakameth; Sura, Thanyachai; Chantratita, Wasun
PUB. DATE
January 2008
SOURCE
Current HIV Research;Jan2008, Vol. 6 Issue 1, p65
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Nevirapine (NVP) is commonly used as a component of first-line antiretroviral therapy in resource-limited countries. We aimed to determine the risk factors for NVP-associated rash among HIV-infected patients who were initiated NVP at low CD4 cell counts in a resource-limited setting. A case-control study was conducted in HIV-infected patients who developed rash after taking NVP (case) and those who did not have rash (control). A total of 357 patients with a mean (SD) age of 36.4 (7.5) years and 52.1%male were included in the study. Mean body weight (SD) was 55.5 (10.5) kg. Of all, 179 (49.0%) patients had a history of AIDS-defining illness and 57 (16.0%) patients had history of drug allergy. Median (IQR) CD4 cell counts at the time of NVP initiation was 95 (31-226) cells/mm3. There were 115 patients in case group and 242 patients in control group. In case group, 43.0%, 54.4%, and 2.6% of patients developed grade 2, 3, and 4 of rash, respectively. Median time to develop rash was 12 (95%CI, 10.5-13.5) days. By logistic regression, history of drug allergy (OR, 3.41; 95%CI, 1.79-6.52), body weight (OR, 1.22 per each 5 kg decrement; 95%CI, 1.08-1.38), CD4 cells counts (OR, 1.20 per each 50 cells/mm3 increment; 95%CI, 1.12-1.30), and AIDS-defining illness (OR, 0.42; 95%CI, 0.25-0.70) were significantly associated with rash. In resource-limited settings where patients were initiated NVP at low CD4 cell counts, history of drug allergy, lower body weight, and higher CD4 cell count are the risk factors for NVP-associated rash. Initiation of NVP in patients with these risks needs closed monitoring.
ACCESSION #
29434692

 

Related Articles

  • HAVE A HARRT.  // Gay Community News;Jun2007, Issue 210, p24 

    The article discusses the highly active anti-retroviral therapy (HAART) drugs and focuses on the reasons why people with HIV are floundering with such drugs. The HAART has revolutionized the treatment of HIV and its development have refined the revolution and mainly focused on minimising side...

  • Structured Intermittent Therapy with Seven-Day Cycles of HAART for Chronic HIV Infection: A Pilot Study in São Paulo, Brazil. Casseb, Jorge; Da Silva Duarte, Alberto Jos // AIDS Patient Care & STDs;Jul2005, Vol. 19 Issue 7, p425 

    In the last 6 years, an impressive impact of the highly active antiretroviral therapy (HAART) on survival and morbidity in HIV-1–infected individuals has been attained. However, their prolonged use may induce metabolic adverse effects such as lipodistrophy, hypertension, diabetes...

  • Has HAART failed? Soresen, Suellyn J.; Busti, Anthony J. // Drug Topics;5/16/2005, Vol. 149 Issue 10, DRUG TOPIC FOR THE... p8 

    Offers advice concerning the condition of an HIV-positive patient who is experiencing virologic failure due to antiretroviral drug interactions. Types of antiretroviral agents being administered to the patient; Increase in drug concentration and toxicity risk; Need for a potent and effective...

  • Antiretrovirals alter ventricular function in children.  // Reactions Weekly;1/16/2010, Issue 1284, p4 

    This article discusses a study on the association between the use of highly-active antiretroviral therapy (HAART) or multiple antiretrovirals and the risk of developing cardiac abnormalities. Presented at the 82nd Annual Scientific Sessions of the American Heart Association, the study involved...

  • Cardiovascular disease risk assessment in HIV: navigating data-sparse zones. Feinstein, Matthew J. // Heart;8/1/2016, Vol. 102 Issue 15, p1157 

    The author comments on the research that investigates the risk assessment for cardiovascular diseases of HIV patients in the U.S. The topics discussed include the effectiveness of antretroviral therapy (ART) in treating their heart diseases, their risks of developing myocardial infarction (MI),...

  • Risk of cardiovascular disease in HIV-infected patients. Das, Satyajit // Journal of Antimicrobial Chemotherapy (JAC);Mar2010, Vol. 65 Issue 3, p386 

    The life expectancy of people living with HIV infection has improved dramatically since the use of highly active antiretroviral therapy (HAART). Now that patients with HIV infection are living longer, the focus of its treatment should shift to long-term management spanning decades. Diseases of...

  • Low Frequency of Renal Function Impairment During One-Year of Therapy with Tenofovir-Containing Regimens in the Real-World: A Case-Control Study. Padilla, Sergio; Gutiérrez, Félix; Masi, Mar; Cánovas, Víctor; Orozco, Carmen // AIDS Patient Care & STDs;Jul2005, Vol. 19 Issue 7, p421 

    Concern exists about the risk of nephrotoxicity using tenofovir (TDF) in HIV-infected patients. We performed a retrospective case-control study including 122 consecutive TDF-naive patients who started treatment with TDF-containing regimens and 194 patients receiving antiretroviral therapy with...

  • Heart Risk Rises With Long-term HIV Drugs. Stephenson, Joan // JAMA: Journal of the American Medical Association;5/4/2005, Vol. 293 Issue 17, p2081 

    Offers a look at heart disease risks associated with long-term HIV treatment with highly active antiretroviral therapy. Reference to a study presented at the Annual Retrovirus Conference by Wafaa El-Sadr of Columbia University's Mailman School of Public Health in New York City; Risk of...

  • Vertigo and Abacavir. Fantry, Lori E.; Staecker, Hinrich // AIDS Patient Care & STDs;Jan2002, Vol. 16 Issue 1, p5 

    Vertigo can cause significant morbidity and make a person unable to perform activities of daily life. A human immunodeficiency virus (HIV)-infected patient experienced vertigo while taking abacavir that resolved immediately on cessation of therapy. The mechanism by which abacavir appeared to be...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics